ut-logo website  
 
Log in
Express registration and login!
If you have a Facebook or LinkedIN account, use one of the buttons on the left to either login or create a new account.

Log in

 

You are here: Home Conferences Conferences ASCO 2012
ASCO 2012 - Prostate Cancer Highlights

ASCO 2012 - Prostate Cancer Highlights

ASCO 2012 - Effect of neoadjuvant abiraterone acetate plus leuprolide acetate on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer: Results of a randomized phase 2 study - Slide Presentation

  • Print

CHICAGO, IL (UroToday.com) - Presented by Mary-Ellen Taplin, MD at the Annual Meeting of the American Society of Clinical Oncology (ASCO)- June 1 - 5, 2012 - McCormick Place - Chicago, IL USA.

Read more...

ASCO 2012 - Effect of neoadjuvant abiraterone acetate plus leuprolide acetate on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer: Results of a randomized phase 2 study - Editor's Commentary

  • Print

BERKELEY, CA (UroToday.com) -

Presentation of the New Paradigms for Hormone Therapy in Prostate Cancer

at the ASCO Annual Meeting

Read more...

ASCO 2012 - An interview with Charles J. Ryan, MD: Presentation of the New Paradigms for Hormone Therapy in Prostate Cancer, clinical symposium at the ASCO 2012 Annual Meeting

  • Print

BERKELEY, CA (UroToday.com) - June 21, 2012 - Translating the clinical results observed from pre-specified interim analyses of the randomized, placebo-controlled phase III study, COU-AA-302 demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS), and all secondary endpoints, compared to patients treated with placebo plus prednisone.

Read more...